Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death risk 42%, but $MRNA dropped ~25% after leaked phase III data. BMO's Evan Seigerman says the selloff reflects inflated expect

What happened: A personalized mRNA vaccine, intismeran, reduced the risk of melanoma returning or the recipient dying by 42% when given with the immunotherapy drug pembrolizumab, according to phase III trial results released after a leak. Key numbers: 42% risk reduction; 1,137 participants across 157 centres; about 25 months of follow-up; Moderna stock fell around 25% after the leak; data were Why it matters: Oncologists quoted in the article call a reduction above 40% exceptional, though an analyst attributed the stock drop to inflated expectations rather than the therapy's efficacy. Coverage: 5 outlets in 24h

A personalized mRNA vaccine, intismeran, reduced the risk of melanoma returning or the recipient dying by 42% when given with the immunotherapy drug pembrolizumab, according to phase III trial results released after a leak.

Oncologists quoted in the article call a reduction above 40% exceptional, though an analyst attributed the stock drop to inflated expectations rather than the therapy's efficacy.